Lenvatinib Combined With PD-1 Inhibitors as First-line Treatment for Unresectable/Advanced Biliary Tract Carcinoma
Clinical trial NCT05509478 · UNKNOWN
Trial details
- NCT number
- NCT05509478
- Sponsor
- The First Hospital of Jilin University
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-08-20
- Primary completion
- 2023-02-01
- Enrollment
- 46
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.